INGELHEIM, Germany, June 8, 2026 /CNW/ - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results